143 related articles for article (PubMed ID: 15454231)
1. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
[TBL] [Abstract][Full Text] [Related]
2. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
5. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
9. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
11. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
12. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
Cumming JG; McKenzie CL; Bowden SG; Campbell D; Masters DJ; Breed J; Jewsbury PJ
Bioorg Med Chem Lett; 2004 Nov; 14(21):5389-94. PubMed ID: 15454232
[TBL] [Abstract][Full Text] [Related]
13. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
15. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
16. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
[TBL] [Abstract][Full Text] [Related]
19. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
20. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
